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Introduction
Hypercholesterolaemia is an important risk factor in the development of coronary artery disease. Following favourable results from interventional studies, the use of cholesterol lowering drugs is becoming widespread."2 In addition to measures aimed at reducing cholesterol levels, patients 'at risk' are often advised to exercise frequently to increase their cardiovascular reserve, help lose weight and improve their sense of well being and thereby reducing their overall risk of coronary heart disease.' We wished to examine whether the aims of increasing exercise and reducing cholesterol using drug therapy are in conflict.
During prolonged aerobic exercise of moderate intensity, much of the required energy is derived from the oxidation of free fatty acids released from adipose tissue' in response to reduced levels of insulin and increased levels of catecholamines, which activate hormone-sensitive lipase.5 If this pathway is interrupted, then exercising muscles become increasingly dependent on glycogen stores, which when depleted, leads to premature exhaustion. 6 We have assessed the impact of three commonly prescribed lipid lowering drugs: simvastatin (an HMG-coenzyme A reductase inhibitor),7 gemfibrozil (a fibric acid derivative known to stimulate lipoprotein lipase)8 and acipimox (a nicotinic acid derivative that inhibits hormonesensitive lipase). 9 On the basis of previous observations,1l0' Basal heart rate, blood pressure and blood were taken 15 minutes and 5 minutes before and blood every 15 minutes during 120 minutes of exercise on a motorized treadmill at an exercise intensity of 50% of the subjects' previously determined maximal oxygen uptake. Expired air was also collected and the rate perceived exertion (RPE) ofthe subject recorded every 15 minutes during the exercise period. The subject consumed water (150 ml every 15 minutes) throughout the exercise to maintain hydration.
Indirect calorimetry
The measurement of oxygen uptake and carbon dioxide excretion was performed using the Douglas bag technique. Total resistance to flow of the gas collection system was 2.0 cm of water at a constant flow of 200 1/minute and within the WHO recommendations.'4 The volume of gas was measured at constant flow using a dry gas meter (Harvard, UK). Aliquots of expired air were analysed for percentage of oxygen and carbon dioxide using a paramagnetic oxygen (Beckmann OM11) and infra-red carbon dioxide meter (Beckmann LB2) previously calibrated with standard gases (BOC Special Gases) certified to an accuracy of 0.05%. Computation ofoxygen uptake and carbon dioxide excretion was performed using the Haldane transformation'5 and the rates of energy expenditure, and the proportion of carbohydrate and fat metabolism calculated using standard equations. '6 Analytical method Blood samples (5 ml) were taken into vacutainers containing potassium oxalate and sodium fluoride, a 500 fl portion of whole blood removed for the measurement ofhaemoglobin and haematocrit and the remainder centrifuged at 5TC and the plasma stored at -70TC prior to enzymatic analysis of glucose,'7 free fatty acids (FFA)'8 and glycerol.'9 All plasma concentrations were corrected for changes in plasma volume.20
Calculation and statistical analysis The total energy expenditure and percentage contribution of carbohydrate and fat to the metabolic mixture for the 120 minutes of exercise was calculated by summation of the values obtained for each 15 minute expired gas sample. The data from these calculations, the heart rate, rate of perceived exertion (RPE) and the measured concentrations of blood substrates were analysed by two-way analysis of variance (ANOVA) with repeated measures in both the condition (that is, drug or placebo treated) and time of sampling. The results are presented as means and standard deviations (s.d.).
Results

Cardiovascular response and exercise tolerance
The mean (n = 24) maximal oxygen uptake (Vo2 max) of 56 + 5.3 ml kg/minute confirmed the subjects as moderately fit but not specifically endurance trained. Randomizing the selection of subjects into groups produced no significant difference in Vo2 max between the groups; 55.6 ± 4.1 Group A; 58 ± 5.2 Group B; 55.4 ± 5.7 Group C. Mean heart rate responses (n = 48) to steady-state submaximal exercise at 50% of Vo2 max were 131 ± 10 after 60 minutes and 137 ± 9 after 120 minutes and did not differ significantly either between groups or between drug and placebo trials.
All subjects successfully completed the exercise trial after placebo. Two subjects failed to complete the exercise trial with acipimox terminating the exercise at 105 minutes. One subject failed to complete the exercise trial with simvastatin terminating the exercise tests at 105 minutes. In none of these subjects were there any signs of increased oxygen consumption, ventilatory response, heart rate or other objective signs of distress. The subjects did, however, perceive the exercise to be more demanding providing RPE scores that were significantly higher (14 vs 10) in response to the drug. The metabolic response of these subjects are considered later. Figure 1 ). The higher, though not significantly higher, contribution of fat as a metabolic fuel in Group C on placebo was because four subjects in this group showed a consistently greater shift to fat oxidation during exercise. Compared to placebo the overall contribution of fat as a metabolic fuel during exercise remained unchanged in response to simvastatin but decreased in response to both gemfibrozil and acipimox (Table II) . Gemfibrozil reduced fat oxidation during exercise (7.5%; P = 0.21 1), the difference from placebo being greatest (10.1%; P= 0.1857) after 120 minutes of exercise. Acipimox suppressed overall fat oxidation by 13.3% (P=0.011). The difference from placebo was most marked during the first 90 minutes of exercise ( Figure Ic) . acipimox. **P <0.01; ****P <0.0001.
group.bmj.com on July 5, 2017 -Published by http://pmj.bmj.com/ Downloaded from respectively. The resting and exercise concentrations of FFA and glycerol were not significantly altered after simvastatin. Compared to placebo, gemfibrozil reduced the resting plasma concentration of free fatty acids from 0.28 ± 0.11 to 0.16 ± 0.02 mmol/l and remained 23% lower than placebo after 120 minutes of exercise (0.91 ± 0.42 vs 1.19 ± 0.26 mmol/l); though the overall response failed to reach statistical significance (P = 0.129). No decrease in plasma glycerol was observed at rest but the rise in plasma glycerol with exercise was lower after gemfibrozil than placebo (0.53 ± 0.12 vs 0.64 ± 0.10 mmol/l; P = 0.089). There was virtually no change in either free fatty acids or glycerol from basal levels during the first 60 minutes of exercise after acipimox. Thereafter, plasma free fatty acids and glycerol rose steadily but were still significantly lower than placebo after 120 minutes of exercise (P = 0.0001).
(c) Plasma glucose There was no significant difference in basal glucose concentrations between any of the groups on either drug or placebo and no significant difference in response to exercise between drug and placebo for any of the drugs under discussion (Figure 5 ).
Discussion
The present study investigated the potential interaction between exercise and a short course of lipid lowering drugs upon the use of fat as a metabolic fuel in normal healthy volunteers. The results of this investigation indicate that a short course of simvastatin had no effect upon substrate metabolism during exercise. The reported mechanism of action of simvastatin is through inhibition of hepatic HMG-coenzyme A reductase, the flux controlling enzyme of cholesterol synthesis.22 Previous studies23 have shown that a prolonged course of simvastatin is known to have little or no effect upon fat metabolism per se and the present data would support this view. One subject did however fail to complete the 120 minute exercise trial after treatment with simvastatin, stopping after 90 minutes with significantly elevated exertional rating (18 vs 14) and a reduction in fat oxidation (25.7 vs 49.4%). The reason for this is not known.
The results obtained with gemfibrozil treatment are of considerable interest but as the changes were not significant they should be considered a possible trend which needs to be evaluated further. However, our observations may suggest ways ofincreasing our understanding of its mechanism of action. It appeared that on gemfibrozil consistently less fat was oxidized than on placebo, and the trend was supported by consistently lower plasma concentrations of FFA. If true, this effect could be explained by either impaired FFA release from adipocytes, or increased metabolism in working muscle. Since the data from indirect calorimetry suggested a reduction in fat oxidation, impaired release of FFA from adipocytes would seem more likely.
Acipimox had a pronounced effect upon the ability to exercise and two subjects failed to complete the exercise test. It is a potent nicotinic acid analogue and is a known anti-lipolytic agent reducing the availability of circulating free fatty acids which supply approximately half of the total fat oxidized by muscle during prolonged submaximal exercise. 24 The pronounced shift in exercise metabolism after acipimox towards a greater reliance upon carbohydrate oxidation, an increased glycogen use' and an increased reliance upon intramuscular triglycerides as the source of fuel for the now reduced level offat oxidation, is the most likely cause of the impairment of exercise tolerance in these subjects.
This study involved healthy males given short courses of treatment. It has shown that drugs do have differing effects upon energy substrates, and that the methods used were a reasonable way to study this subject. Further studies are now needed to (a) assess the effects of chronic therapy, (b) to determine the relevance of our observations in a patient population, and (c) to investigate further the biochemical processes modified by these drugs during exercise.
